Please login to the form below
Intercept
This page shows the latest Intercept news and features for those working in and with pharma, biotech and healthcare.
Merck enters agreement with Hanmi for investigational NASH drug
Intercept Pharmaceuticals is awaiting a US Food and Drug Administration (FDA) review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again
Latest news
-
Genfit scraps phase 3 trial of experimental NASH drug
Another potential competitor – Intercept Pharmaceuticals – is still awaiting an FDA review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again in
-
Zydus Cadila scores first ever NASH approval, in India
Another potential treatment for NASH – from Intercept – is currently under review with the US Food and Drug Administration (FDA). ... additional information provided in response to FDA requests,” Intercept wrote in the filing at the time.
-
FDA delays decision on Intercept's NASH drug by three months
Intercept confirmed the delay in a filing with the US Securities &Exchange Commission last week. ... additional information provided in response to FDA requests,” Intercept wrote in the filing.
-
Boehringer bolsters NASH pipeline with Enleofen link-up
Meanwhile, Intercept Pharma’s obeticholic acid (OCA) is under priority review at the FDA for the treatment of liver fibrosis due to NASH, and could become the first drug to treat
-
Provention Bio wins PRIME designation for type 1 diabetes prevention drug
1R inhibition intercepts the migration of inflammatory cells to the gut.
Genfit scraps phase 3 trial of experimental NASH drug
Zydus Cadila scores first ever NASH approval, in India
FDA delays decision on Intercept's NASH drug by three months
Boehringer bolsters NASH pipeline with Enleofen link-up
Provention Bio wins PRIME designation for type 1 diabetes prevention drug
More from news
Approximately 10 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
Unlocking the potential of precision medicine in oncology
In this endeavour to eradicate or intercept cancer, it is our duty to account for distinct differences in people’s ‘-omics’ spectrum, but also importantly in their clinical, psychosocial and professional
-
Deal Watch June 2016
In Europe Cerus expects to apply for a CE Mark for the Intercept RBC System in the second half of 2016. ... collaboration, licence. 200. Cerus/ BARDA. Intercept, pathogen reduction technology for blood transfusions including Zika virus.
Unlocking the potential of precision medicine in oncology
Deal Watch June 2016
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Simon Doyle joins STEM
Doyle - who joins the group from Intercept Pharmaceuticals where he was executive director of commercial operations and marketing - will be at the forefront of a number of key accounts to help
-
Glenn Sblendorio to retire as president of The Medicines Company
He currently serves as a director at Amicus Therapeutics, Intercept Pharmaceuticals and Ophthotech Corporation.
Simon Doyle joins STEM
Glenn Sblendorio to retire as president of The Medicines Company
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Pharma, Technology, and Healthcare in the New Normal
Brian Canestraro, General Manager at Intercept Pharmaceuticals, discusses a range of hot topics, from Brian’s leadership lessons and tips to the impact of the COVID-19 pandemic on the way
-
Blog: 5 ingredients: Multichannel marketing, simplified
Develop your communication for each channel specifically. Intercept testing: show the ad to your mother, your child, a co-worker down the hall.
-
Market Insights Can Deliver a Better Patient Experience
Our survey, carried out using a mobile research intercept method, found that, unfortunately, memory aids can give patients the false reassurance that they are more compliant than they actually are.
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
-
Digital account director
-
Competitive
-
Digital project manager
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- GSK reveals plans for £400m R&D facility expansion in England
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med
- British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Pharma’s authentic proof of purpose influences decisions among HCPs and payers
- Merck & Co's cancer drug Keytruda gaining traction in US
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
